HOHiromasa Otake

Hiromasa Otake

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiromasa Otake has a total of 504 co-authors. Here are the top co-authors by number of shared publications:

  • Toshiro Shinke

    Division of Cardiology, Showa University School of Medicine

    47 shared publications
  • Takayoshi Toba

    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, KobeKobe, Japan

    32 shared publications
  • Ken-Ichi Hirata

    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

    30 shared publications
  • Hiroyuki Kawamori

    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, KobeKobe, Japan

    28 shared publications
  • Ken-Ichi Hirata

    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, KobeKobe, Japan

    28 shared publications
  • Tomofumi Takaya

    Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center , 3-264 Kamiya-cho, Himeji 670-8560

    25 shared publications

Latest Publications

  • Open Access

    Optical Coherence Tomography Characterization of Coronary Lithotripsy Following Atherectomy for Treatment of Severely Calcified Lesions

    by Yohei Sotomi, Nehiro Kuriyama, Yutaka Tanaka, Seiji Yamazaki, Tomohiro Kawasaki, Kazushige Kadota, Takashi Muramatsu, Akihiko Takahashi, Takashi Ashikaga, Kenji Ando, et al.

    BACKGROUND: A combined strategy of atherectomy followed by intravascular lithotripsy (dual-prep strategy) for severely calcified lesions may optimize stent deployment, but mechanistic evidence from prospective optical coherence tomography (OCT) imaging is limited. This study was designed to comprehensively characterize patterns of calcium modification during a dual-preparation strategy and to explore imaging determinants of calcium fracture and stent expansion using serial and 3-dimensional OCT assessment. METHODS: This was a prespecified, multicenter, single-arm OCT substudy of the DUAL-PREP (atherectomy Devices and intravascUlAr Lithotripsy for the PREParation of heavy calcified coronary lesions) registry, enrolling patients with severely calcified lesions for whom combined treatment with atherectomy and intravascular lithotripsy was deemed preferable based on imaging findings. OCT was analyzed by an independent core laboratory. Multivariable models examined predictors of fracture and stenting performance, including calcium thickness, length, angle, calcified nodules, and morphology (circumferential, eccentric spiral, and eccentric straight types). RESULTS: OCT images were available for 114 of 118 patients (116 lesions; age, 75.9±9.1 years; 69.3% male). All lesions had an OCT calcium score of 4. Calcium fractures were uncommon after atherectomy (2/106 lesions [1.9%]) but markedly increased following intravascular lithotripsy (89/106 lesions [84.0%]; 2.05±1.59 fractures per lesion), with a further increase after stent implantation (101/109 lesions [92.7%]; 2.89±1.67 fractures per lesion). Final stent expansion index was 0.81±0.15 (eccentricity, 0.72±0.09; asymmetry, 0.39±0.15). Eccentric straight-type calcification was associated with a lower likelihood of fracture at final OCT (odds ratio, 0.07 [95% CI, 0.00–0.77]; P =0.029), whereas eccentric spiral and circumferential types showed higher fracture occurrence. CONCLUSIONS: This OCT analysis demonstrated a stepwise increase in calcium fracture during a dual-preparation strategy, with minimal fracture after atherectomy, a marked increase following intravascular lithotripsy, and a further increase after stent implantation. Calcium morphology may provide additional insight into fracture occurrence, supporting the potential value of 3-dimensional assessment in severely calcified lesions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: jRCT1032230384.


  • Open Access

    Sushi, von Willebrand Factor Type A, EGF and Pentraxin Domain‐Containing Protein 1: A Novel Fibroblast‐Derived Circulating Biomarker Reflecting Cardiac Fibrosis

    by Naoya Kuwahara, Manabu Nagao, Yu Izawa, Kenta Kaneshiro, Hiromi Hashimura, Takeshi Yoshida, Takuo Emoto, Takayoshi Toba, Hidekazu Tanaka, Tatsuro Ishida, et al.

    Background: Cardiac fibrosis is a hallmark of heart failure and can be quantified by the extracellular volume fraction (ECV) derived from diagnostic imaging. However, noninvasive assessment is limited by the lack of specific circulating biomarkers. Recent large plasma proteome analyses have identified SVEP1 (Sushi, von Willebrand factor type A, EGF, and pentraxin domain containing 1) as candidate molecules reflecting cardiac fibrosis. This study aimed to evaluate SVEP1 as a biomarker for cardiac fibrosis. Methods: In 72 patients with heart failure due to aortic stenosis, computed tomography‐based ECV, serum SVEP1, and BNP (brain natriuretic peptide) levels were assessed. Multivariable regression was used to determine independent predictors of ECV. Publicly available single‐nucleus RNA sequencing of human hearts revealed the cellular origin of SVEP1 . SVEP1 secretion was assessed in human cardiac fibroblasts after TGF‐β (transforming growth factor‐β) stimulation or small interfering RNA knockdown. Plasma Svep1 and cardiac hydroxyproline levels were measured in mice with angiotensin II‐ and phenylephrine‐induced cardiac fibrosis. Results: Serum SVEP1 correlated with ECV and outperformed BNP in detecting fibrosis. Multivariable analysis revealed SVEP1 as an independent predictor of ECV. In addition, snRNA‐seq revealed fibroblast‐specific expression, expanded in failing hearts consistent with activated fibroblast emergence. Furthermore, TGF‐β increased SVEP1 secretion in human cardiac fibroblasts, whereas its knockdown reduced SVEP1 secretion. Plasma Svep1 and cardiac hydroxyproline levels were elevated and positively correlated in mice. Conclusions: Compared with BNP, SVEP1, derived from cardiac fibroblasts, is more strongly associated with ECV‐defined fibrosis and may serve as a novel fibrosis‐specific circulating biomarker in heart failure.

  • Prognostic Utility of Perivascular Adipose Tissue Attenuation in Patients Undergoing Endovascular Aneurysm Repair for Abdominal Aortic Aneurysms

    by Koshi Matsuhama, Takayoshi Toba, Yoichiro Sugizaki, Tatsuya Kitagawa, Shotaro Yoshida, Mayuka Masuda, Keisuke Iida, Ken Takata, Nobuhiro Watanabe, Kotaro Higuchi, et al.

    BACKGROUND: Perivascular adipose tissue (PVAT) attenuation on computed tomography angiography reflects vascular inflammation. However, its prognostic value in patients undergoing endovascular aortic repair (EVAR) for abdominal aortic aneurysm (AAA) remains unclear. METHODS: We retrospectively studied consecutive patients who underwent EVAR for unruptured infrarenal AAA with preprocedural computed tomography angiography. PVAT attenuation and aortic characteristics were assessed using computed tomography angiography. The primary outcome was major adverse cardiac or cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, stroke, and any vessel treatment. RESULTS: Among 275 patients treated with EVAR, 35.6% (98/275) experienced MACCE during a median follow-up of 3.5 years. Pre-EVAR PVAT attenuation was higher in patients who experienced MACCE than in those who did not (−69.8±10.3 HU versus −77.3±8.6 HU; P P <0.001) was associated with MACCE after EVAR. Furthermore, higher PVAT attenuation was associated with AAA-related adverse events: a composite of AAA-related death, reintervention for AAA, embolization for endoleak, and AAA enlargement (per 10 HU; unadjusted hazard ratio, 2.16 [95% CI, 1.59–2.94]). Adding PVAT attenuation to post-EVAR prognostic factors and computed tomography angiography findings improved the predictive and reclassification abilities for MACCE after EVAR. CONCLUSIONS: In patients undergoing EVAR, higher PVAT attenuation was associated with both MACCE and AAA-related adverse events. PVAT attenuation may provide incremental prognostic value for identifying patients at higher risk of unfavorable outcomes following EVAR.


  • Top Cited Papers
    Open Access

    Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH

    by Novia Nurul Faizah, Gusty Rizky Teguh Ryanto, Sagita Mega Sekar Kencana, Yoko Suzuki, Tetsuya Hara, Hiromasa Otake, Noriaki Emoto

    BACKGROUND: Pulmonary arterial hypertension remains a life-threatening disease despite advances in vasodilator therapy. Vascular remodeling, partly driven by pulmonary artery endothelial cell dysfunction, is accompanied by vasoactive mediators imbalance such as ET-1 (endothelin-1). Although endothelin receptor antagonists alleviate vasoconstriction, they incompletely address the remodeling process. We previously reported how endothelial-derived activin A promotes vascular remodeling, leading to the clinical development of the activin signaling inhibitor sotatercept, which improves outcomes when added to endothelin receptor antagonists. As both activin A and ET-1 originate from endothelial cells and promote remodeling, we investigated whether activin A regulates ET-1 production and activity in pulmonary arterial hypertension. METHODS: In vitro, we used pulmonary artery endothelial cell models of activin A overabundance alone or cocultured with pulmonary artery smooth muscle cells. Cells were treated with either the activin A inhibitor FST (follistatin), the endothelin receptor antagonist bosentan, the FST/bosentan combination, or vehicle for analysis. In vivo, we exposed wild-type or endothelial-specific INHBA (inhibin β-A)-overexpressing mice (VEcadherin-INHBA-Transgenic/VEcad-INHBA-Tg) to chronic hypoxia pulmonary hypertension model, with the addition of FST, bosentan, FST and bosentan, or vehicle treatments after the first week of hypoxia exposure. RESULTS: Activin A upregulated ET-1 expression via canonical SMAD2/3 (small mother against decapentaplegic family member 2/3) signaling in pulmonary artery endothelial cells. This induction, as well as ET-1–driven downstream effects—including reduced eNOS (endothelial NO synthase), pulmonary artery smooth muscle cell phenotypic switching, oxidative stress, and endothelial-to-mesenchymal transition—was reversed by FST alone or in combination with bosentan. In vivo, FST-based therapy achieved greater hemodynamic, right ventricular remodeling, and vascular structural normalization in wild-type and VEcad-INHBA-Tg mice than bosentan alone, accompanied by stronger ET-1 suppression. CONCLUSIONS: We identified ET-1 as a downstream effector of activin A in pulmonary arterial hypertension development, supporting activin A blockade as a strategy to inhibit ET-1–mediated vasoconstriction and remodeling. This mechanistic link provides a rationale for the rapid clinical benefits observed with sotatercept and suggests its potential role earlier in the pulmonary arterial hypertension treatment paradigm.


  • Prognostic Impact of Renal Function on Outcomes After Physiology-Guided Coronary Revascularization: Insights From the J-PRIDE Registry

    by Hirofumi Ohashi, Shoichi Kuramitsu, Hirohiko Ando, Tomohiro Shinozaki, Yoshiaki Kawase, Takenori Domei, Futoshi Yamanaka, Umihiko Kaneko, Tsunekazu Kakuta, Kazunori Horie, et al.

    BACKGROUND: The clinical utility of physiology-guided revascularization for decision-making in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains uncertain. The aim of this study is to evaluate the diagnostic performance and prognostic significance of fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs) according to the severity of CKD. METHODS: This subanalysis of the J-PRIDE registry, a prospective multicenter study conducted at 20 Japanese centers between September 2019 and February 2021, included 4296 lesions from 3194 patients who underwent both FFR and NHPR assessment. Patients were categorized by estimated glomerular filtration rate into non-CKD (≥60 mL/min per 1.73 m 2 ; n=1639), CKD (15–59; n=1321), and ESRD (P P =0.001). The NHPR cutoff predicting FFR ≤0.80 was lower in ESRD compared with CKD and non-CKD (0.85 versus 0.89 versus 0.89). Although the overall prevalence of FFR/NHPR discordance was comparable (23.6%, 19.7%, and 19.7%; P =0.24), FFR−/NHPR+ discordance predominated in ESRD (18.6% versus 9.3% versus 7.0%; P <0.001). FFR−/NHPR+ lesions in the ESRD group exhibited an excess risk compared with other lesions. Revascularization was beneficial in non-CKD patients with FFR+/NHPR− lesions, whereas no clear benefit was observed in patients with CKD and ESRD. CONCLUSIONS: Patients with ESRD exhibited distinct physiological characteristics and substantially worse outcomes, highlighting the need for tailored coronary revascularization strategies in this population. REGISTRATION: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000038403.

  • Open Access

    Impact of Perivascular Adipose Tissue Attenuation Around the Aortic Valve on Clinical Outcomes After Transcatheter Aortic Valve Replacement

    by Hiroya Okamoto, Takayoshi Toba, Yoichiro Sugizaki, Hiroyuki Kawamori, Takashi Hiromasa, Daichi Fujimoto, Yu Izawa, Yuto Osumi, Tetsuya Yamamoto, Seigo Iwane, et al.

    Background: Perivascular adipose tissue (PVAT) attenuation interacts with local and systemic vascular inflammation and consequently contributes to unfavorable clinical outcomes in patients with various cardiovascular diseases. Methods: We retrospectively analyzed consecutive patients with severe aortic stenosis to investigate the association between PVAT attenuation measured before transcatheter aortic valve replacement (TAVR) and subsequent clinical outcomes. PVAT attenuation was measured using computed tomography angiography images around the aortic valve. The primary outcome was defined as major adverse cardiovascular events (MACE), a composite of all‐cause death, stroke, and heart failure rehospitalization. Results: MACE was observed in 23.6% of 233 patients during a median follow‐up of 2.2 years. The MACE group had significantly higher PVAT attenuation than the non‐MACE group (−74.0±9.8 Hounsfield unit [HU] versus −78.9±9.2 HU, P =0.001). In the Cox regression model, higher PVAT attenuation was independently associated with MACE (hazard ratio: 1.52 [95% CI: 1.13–2.04], P =0.006). Incorporating PVAT attenuation into established prognostic factors following TAVR improved the predictive and reclassification performance of MACE risk. Conclusions: Elevated PVAT attenuation around the aortic valve was associated with MACE in patients undergoing TAVR. Measuring PVAT attenuation before TAVR can help identify patients at higher risk of developing heart failure or cardiovascular death after TAVR, thereby aiding in treatment strategy decisions. Registration: URL: https://www.umin.ac.jp/ctr/ ; Unique Identifier: UMIN000057107.


  • Open Access

    Vessel‐Specific Myocardial Mass in Patients With Stable Coronary Artery Disease

    by Nikolaos Stalikas, Takuya Mizukami, Frederic Bouisset, Kazumasa Ikeda, Atomu Tajima, Daniel Munhoz, Thabo Mahendiran, Adriaan Wilgenhof, Koshiro Sakai, Bjarne Noorgard, et al.

    Background: Assessing the myocardial mass at risk is essential in evaluating patients with coronary artery disease. This study aims to establish reference values for vessel‐specific myocardial mass derived from coronary computed tomography angiography, providing a quantitative assessment of the myocardial mass subtended by each epicardial vessel. Methods: Left ventricular (LV) and vessel‐specific myocardial mass were calculated from coronary computed tomography angiography using the Voronoi method in patients with stable coronary artery disease. Myocardial mass was quantified for each epicardial coronary artery with a diameter >1.5 mm. Results: We included 948 patients with 9228 epicardial coronary artery branches. Mean age was 66±9 years. The cohort was predominantly male (77%); 66% had hypertension, and 22% had diabetes. Vessel‐specific myocardial mass was calculated for 2767 main epicardial arteries (948 left anterior descending, 948 left circumflex, and 871 right coronary artery) and 6461 side branches (1888 diagonals, 1208 septals, 1422 obtuse marginals, 247 ramus intermedius, 850 right posterior descending, and 846 posterolateral branches). Median LV mass was 141 grams (interquartile range 118–166); women had smaller LV mass than men (106 [93–123] grams versus 150 [132–173] grams, P <0.001). On average, the left anterior descending subtended 42.5% [37.9–48.1] of LV mass, the left circumflex artery 28.8% [21.9–5.7], and the right coronary artery 26.4% [20.9–31.9]. Median LV mass subtended by the first septal, first diagonal, and first obtuse marginal were 8.9% [6.4–11.1], 7.9% [4.52–2.0], and 10.2% [4.52–12.0], respectively. Conclusions: This study quantified the myocardial mass subtended by each major artery in the coronary circulation. Understanding the vessel‐specific mass at risk has significant clinical implications for personalizing revascularization strategies. Registration: This is a retrospective analysis of 5 prospectively conducted trials (P3: NCT03782688; P4: NCT05253677; PPG Global: NCT04789317; Euro‐CRAFT: NCT05805462; INSIGHTFUL‐FFR: NCT05437900). No additional registration was required.


  • Beyond Angiography

    by Hiromasa Otake


  • Prognostic significance of angiography-derived index of microcirculatory resistance assessment after rotational atherectomy in patients with severely calcified lesions

    by Yuki Sakamoto, Hiroyuki Kawamori, Takayoshi Toba, Satoru Sasaki, Hiroyuki Fujii, Tomoyo Hamana, Yuto Osumi, Seigo Iwane, Tetsuya Yamamoto, Shota Naniwa, et al.

    Coronary microcirculatory dysfunction (CMD) is a known predictor of adverse outcomes after percutaneous coronary intervention (PCI). However, the prognostic significance of CMD in patients with severely calcified lesions treated with rotational atherectomy (RA) remains unclear. We retrospectively studied consecutive chronic coronary syndrome patients who underwent PCI with RA followed by second-generation drug-eluting stent (DES) implantation. CMD was evaluated by angiography-derived index of microcirculatory resistance (IMRangio), calculated from the quantitative flow ratio (QFR) obtained immediately after PCI without hyperemia. The primary outcome was the occurrence of major adverse cardiovascular events (MACE) within 2 years, including cardiovascular death, spontaneous myocardial infarction, and target vessel revascularization. Among the 128 enrolled patients, 22 (17.2%) experienced MACE. Post-IMRangio was significantly higher in patients who experienced MACE than in those who did not (39.3 ± 12.5 vs. 30.4 ± 9.8, p < 0.001). Increased post-IMRangio was independently associated with MACE (hazard ratio, 1.05; 95% confidence interval [CI]: 1.02–1.09, p = 0.004). Receiver operating characteristic curve analysis identified optimal cutoff values of 40.6 for post-IMRangio to predict MACE (area under the curve 0.72, 95% CI: 0.58–0.86). Including high post-IMRangio (> 40U), along with clinical risk factors and QFR findings, significantly improved the discriminatory and reclassification ability to identify the risk of MACE after RA. IMRangio measured immediately after the PCI with RA followed by second-generation DES implantation is a valuable tool for risk stratification in patients with severely calcified lesions.


  • ACLY Promotes Cardiac Fibrosis via the Regulation of DNL and Histone Acetylation

    by Naoya Kuwahara, Manabu Nagao, Masakazu Shinohara, Kenta Kaneshiro, Takuo Emoto, Takeshi Yoshida, Terunobu Fukuda, Makoto Nishimori, Seimi Satomi-Kobayashi, Hiromasa Otake, et al.

    BACKGROUND: ATP citrate lyase (ACLY) is a key enzyme in de novo lipogenesis that generates acetyl-CoA from citrate. Although fatty acids are required for energy production and biomass synthesis in the heart, the regulatory mechanisms of ACLY-mediated de novo lipogenesis in pathological cardiac fibroblasts remain unknown. The aim of this study was to investigate the biological role of ACLY in cardiac remodeling. METHODS: Adeno-associated virus serotype 9-mediated shRNA targeting Acly was intravenously injected into C57BL/6J male mice. The mice were subsequently continuously infused with a mixture of angiotensin II and phenylephrine. Cardiac phenotypes were evaluated via histological staining. Cell proliferation assays, stable isotope tracing with 13C-labeled glucose, and chromatin immunoprecipitation assays were performed using human cardiac fibroblasts. RESULTS: ACLY expression was upregulated in the heart sections of mice treated with angiotensin II/phenylephrine, in particular in fibrotic areas. Masson trichrome staining revealed that Acly gene silencing significantly reduced cardiac fibrosis in these mice. Both siRNA-mediated ACLY knockdown and pharmacological ACLY inhibition suppressed the proliferation and expression of fibrous proteins in cultured human cardiac fibroblasts stimulated with transforming growth factor-β. Mechanistically, ACLY inhibition reduced de novo lipogenesis, limiting the fatty acid supply essential for cellular growth and proliferation. It also decreased H3K9 and H3K27 acetylation, in addition to the presence of acetylated H3K9 and H3K27 at the promoter regions of fibrotic genes. CONCLUSIONS: Our findings demonstrate that ACLY plays an important role in maladaptive cardiac fibrosis. ACLY could be a novel therapeutic target to prevent the development of heart failure.